Demonstration of heterodimeric fibrinogen molecules partially conjugated with albumin in a novel dysfibrinogen: Fibrinogen Mannheim V

Thrombosis and Haemostasis

Volumn 102, Issue 1, 2009, Pages 29-34

  Dempfle, Carl Erik ^a   George, Peter M ^b   Borggrefe, Martin ^a   Neumaier, Michael ^a   Brennan, Stephen O ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Dysfibrinogenemia; Fibrinogen; Pregnancy complications; Recurrent abortions

Indexed keywords

ALBUMIN; AMINO ACID; FIBRINOGEN; FIBRINOGEN VARIANT; HAEMOCOMPLETTAN; MANNHEIM V; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CODON; DYSFIBRINOGENEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; FIRST TRIMESTER PREGNANCY; GENE AMPLIFICATION; GENE SEQUENCE; HETEROZYGOSITY; HUMAN; IMMUNOBLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREGNANCY COMPLICATION; PRIORITY JOURNAL; SPONTANEOUS ABORTION;

ABORTION, HABITUAL; ADULT; AMINO ACID SEQUENCE; DIMERIZATION; FEMALE; FIBRINOGENS, ABNORMAL; GENETIC VARIATION; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; POINT MUTATION; PREGNANCY; SERUM ALBUMIN;

EID: 67749108084     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-09-0559     Document Type: Article

References (29)

1. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 11-30.
2. Madrazo J, Brown JH, Litvinovich S, et al. Crystal structure of the central region of bovine fibrinogen (E5 fragment) at 1.4-A resolution. Proc Natl Acad Sci USA 2001; 98: 11967-11972.
3. Holm B, Nilsen DW, Kierulf P, et al. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res 1985; 37: 165-176.
4. Dempfle CE, Pfitzner SA, Schott D, et al. Fibrinogen heterogeneity in homozygous plasminogen deficiency type I: further evidence that plasmin is not involved in formation of LMW- and LMW′-fibrinogen. Thromb Haemost 1997; 77: 879-883.
5. Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 1980; 77: 1374-1378.
6. Budzynski AZ, Olexa SA, Pandya BV. Fibrin polymerization sites in fibrinogen and fibrin fragments. Ann NY Acad Sci 1983; 408: 301-314.
7. Litvinov RI, Gorkun OV, Galanakis DK, et al. Polymerization of fibrin: Direct observation and quantification of individual B:b knob-hole interactions. Blood 2007; 109: 130-138.
8. Greenberg CS, Achyuthan KE, Rajagopalan S, et al. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII. Arch Biochem Biophys 1988; 262: 142-148.
9. Mosesson MW. Fibrinogen structure and fibrin clot assembly. Semin Thromb Hemost 1998; 24: 169-174.
10. Matsuda M. Structure and function of fibrinogen inferred from hereditary dysfibrinogens. Int J Hematol 2000; 72: 436-447.
11. Siebenlist KR, Prchal JT, Mosesson MW. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg - His) containing heterodimeric molecules. Blood 1988; 71: 613-618.
12. Galanakis DK, Henschen A, Peerschke EI, et al. Fibrinogen Stony Brook, a heterozygous A alpha 16Arg - Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly. J Clin Invest 1989; 84: 295-304.
13. Okumura N, Terasawa F, Fujita K, et al. Evidence that heterodimers exist in the fibrinogen Matsumoto II (gamma308N - >K) proband and participate in fibrin fiber formation. Thromb Res 2002; 107: 157-162.
14. Homer VM, Mullin JL, Brennan SO, et al. Novel Aalpha chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization. J Thromb Haemost 2003; 1: 1245-1250.
15. Koopman J, Haverkate F, Grimbergen J, et al. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA - >stop TAA). Blood 1992; 80: 1972-1979.
16. Collen A, Maas A, Kooistra T, et al. Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation. Blood 2001; 97: 973-980.
17. Margaglione M, Vecchione G, Santacroce R, et al. A frameshift mutation in the human fibrinogen Aalpha-chain gene (Aalpha(499)Ala frameshift stop) leading to dysfibrinogen San Giovanni Rotondo. Thromb Haemost 2001; 86: 1483-1488.
18. Marchi R, Carvajal Z, Meyer M, et al. Fibrinogen Guarenas, an abnormal fibrinogen with an Aalpha-chain truncation due to a nonsense mutation at Aalpha 467 Glu (GAA) - >stop (TAA). Thromb Res 2006; 118: 637-650.
19. Ridgway HJ, Brennan SO, Gibbons S, et al. Fibrinogen Lincoln: a new truncated alpha chain variant with delayed clotting. Br J Haematol 1996; 93: 177-184.
20. Marchi R, Meyer M, de Bosch N, et al. Biophysical characterization of fibrinogen Caracas I with an Aalpha-chain truncation at Aalpha-466 Ser: identification of the mutation and biophysical characterization of properties of clots from plasma and purified fibrinogen. Blood Coagul Fibrinolysis 2004; 15: 285-293.
21. Soria J, Soria C, Caen P. A new type of congenital dysfibrinogenaemia with defective fibrin lysis - Dusard syndrome: possible relation to thrombosis. Br J Haematol 1983; 53: 575-586.
22. Siebenlist KR, Mosesson MW, DiOrio JP, et al. The polymerization of fibrinogen Dusart (A alpha 554 Arg - >Cys) after removal of carboxy terminal regions of the A alpha-chains. Blood Coagul Fibrinolysis 1993; 4: 61-65.
23. Koopman J, Haverkate F, Grimbergen J, et al. Molecular basis for fibrinogen Dusart (A alpha 554 Arg - >Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 1993; 91: 1637-1643.
24. Collet JP, Woodhead JL, Soria J, et al. Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys J 1996; 70: 500-510.
25. Mosesson MW, Siebenlist KR, Hainfeld J, et al. The relationship between the fibrinogen D domain self-association/cross-linking site (gammaXL) and the fibrinogen Dusart abnormality (Aalpha R554C-albumin): clues to thrombophilia in the "Dusart syndrome". J Clin Invest 1996; 97: 2342-2350.
26. Lijnen HR, Soria J, Soria C, et al. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 1984; 51: 108-109.
27. Ridgway HJ, Brennan SO, Faed JM, et al. Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98: 632-639.
28. Edwards RZ, Rijhsinghani A. Dysfibrinogenemia and placental abruption. Obstet Gynecol 2000; 95: 1043.
29. Yamanaka Y, Takeuchi K, Sugimoto M, et al. Dysfibrinogenemia during pregnancy treated successfully with fibrinogen. Acta Obstet Gynecol Scand 2003; 82: 972-973.